Brunner S, Theiss HD, Murr A, Negele T, Franz W-M. Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells.
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ϩ cells indicating progenitor cells with the homing receptor CXCR4). Cytokine serum levels (SCF, SDF-1, VEGF, EPO, and G-CSF) were assessed using ELISA. Levels of PTH and thyroid hormone as well as serum electrolytes, renal and liver parameters, and blood count were analyzed. Our data show for the first time a significant increase of circulating BMCs and an upregulation of SDF-1 and VEGF serum levels in patients with PHPT. The number of circulating BMCs returned to control levels measured 16.7 Ϯ 2.3 mo after surgery. There was a positive correlation of PTH levels with the number of CD45
ϩ /c-kit ϩ , and CD45 ϩ /CD34 ϩ /CXCR4 ϩ cells. However, there was no correlation between cytokine serum concentrations (SDF-1, VEGF) and circulating BMCs. Serum levels of G-CSF, EPO, and SCF known to mobilize BMCs were even decreased or remained unchanged, suggesting a direct effect of PTH on stem cell mobilization. Our data suggest a new function of PTH mobilizing BMCs into peripheral blood. parathyroid hormone; mobilization; cytokines BONE MARROW-DERIVED PROGENITOR CELLS (BMC) are the source of all mature blood cells. They reside in niches of bone marrow and can be released into the circulation (1, 38) . Mobilization of BMC into peripheral blood occurs in response to different stimuli, including chemokines, hormones, and growth factors (2, 6, 11, 12, 14, 16, 19, 24, 32, 33) . Endothelial progenitor cells (EPC) are a subpopulation of BMC known to contribute to vessel formation and restoration (8, 13, 34, 36) . Mobilization of EPC can also be induced by traumatic vascular injury or other forms of physiological stress like tissue ischemia or physical exercise (9, 19, 28, 32) . Furthermore, low levels of circulating EPC represent a negative prognostic marker for cardiovascular events and subsequent death (35) . In experimental and clinical trials, EPC have been used for the treatment of ischemic disease, leading to a restored blood flow, increased capillary density, and an improved cardiac function (5, 7, 15, 17, 23, 24, 27, 39) . Besides their vasculoprotective function, EPC can also play a maladaptive role in tumor progression (17, 25, 26) . It has been demonstrated (25, 26) that EPC may infiltrate tumors and give rise to up to 16% of the tumor neovascularization.
Starting in the late 1950s, an effect of parathyroid hormone (PTH) on the hematopoietic system was shown. Administration of PTH stimulated proliferation of murine colony-forming unit spleen and bone marrow cells via cAMP, leading to an increased survival of X-irradiated mice (37) . Recently, Calvi et al. (4) were able to demonstrate that PTH strengthens survival and self-renewal of hematopoietic BMC by activating osteoblasts. In addition, activated osteoblasts were shown (18, 22, 29 -31) to increase the production of growth factors known to enhance mobilization of BMC into the peripheral blood. In the present study we wanted to investigate the effect of primary hyperparathyroidism (PHPT), a condition of sustained PTH stimulation, on mobilization of BMC.
PATIENTS AND METHODS

Patients.
Twenty-four patients with untreated PHPT and 10 controls were enrolled into the study prospectively. The patients with PHPT included in the study (15 women and 9 men) were recruited from the Department of Surgery at the Hospital MarthaMaria in Munich, Germany. The inclusion criteria for the PHPT group comprised an increased total serum concentration of calcium (Ͼ2.65 mmol/l), an inappropriately high serum level of PTH (Ͼ67 pg/ml), serum creatinine Ͻ1.3 mg/dl, postoperative normalization of serum calcium, and sonographic and histological confirmation of parathyroid adenoma (3, 10) . The mean age of the patients was 58.7 Ϯ 17.3 yr (range 26 -80 yr), and their mean total serum calcium concentration was 2.88 Ϯ 0.04 mmol/l before parathyroid surgery. Laboratory findings are summarized in Table 1 .
Eight patients were on antihypertensive or antianginal treatment in various combinations before surgery. Three had ␤-blockers, one had a calcium channel blocker, five had angiotensin-converting enzyme inhibitors, and three had diuretics. Besides typical concomitant PHPTdependent disorders, patients suffered from the following disorders: one had non-insulin-dependent diabetes mellitus, two suffered from coronary artery disease without signs or symptoms of congestive heart failure, 13 patients had a multinodular goiter with normal levels of TSH, free triiodothyronine (FT 3), and free thyroxine (FT4), and two suffered from papillary thyroid carcinoma. Clinical characteristics are presented in Table 2 .
The control group was age matched and unpaired. Control subjects had no severe disorders. However, seven of the controls receiving ␤-blockers, angiotensin-converting enzyme inhibitors, and/or diuretics suffered from arterial hypertension.
Initially, 24 patients with PHPT were assessed for the study. However, two did not fulfill inclusion criteria. Blood samples were taken 12-24 h before surgery. Fourteen of 22 samples were utilizable for cytometric analyses. Eight patients agreed to followup examinations, which were performed 16.7 Ϯ 2.3 mo after surgery.
The purpose, nature, and potential risks of the study were explained to the patients before their written, informed consent was obtained. The protocol was approved by the Ethics Committee on Human Research of the Ludwig-Maximilians University of Munich, Germany.
Quantification of BMC. Cytometric analyses were performed using a flow cytometer (FACScan; Becton Dickinson, Heidelberg, Germany) according to International Society of Hematotherapy and Graft Engineering guidelines and to a standard protocol (21 Biochemical measurements. Prior to surgery the following routine laboratory parameters were assessed: serum concentration of intact PTH, total calcium, inorganic phosphate, sodium, potassium, creatinine, urea nitrogen, aminotransferases, gammaglutamyl transpeptidase, alkaline phosphatase, glucose, complete blood count (including Hb), Hct, leukocytes, and platelets. In addition, thyroid parameters TSH, FT 3, and FT4 were measured. Serum levels of stem cell factor (SCF), stromal cell-derived factor 1 (SDF-1), VEGF, erythropoietin (EPO), and granulocyte colony-stimulating factor (G-CSF) were analyzed using ELISA (R & D Systems, Wiesbaden, Germany).
Statistical analysis. Results are expressed as means Ϯ SE as indicated. Comparisons between two groups were performed using the unpaired t-test. Values of P Ͻ 0.05 were considered statistically significant. Comparison of categoric variables was generated by the 2 Pearson test. Statistics were calculated using SPSS for Windows (release 14.0; SPSS, Chicago, IL).
RESULTS
Clinical characteristics.
Patients with PHPT showed characteristic laboratory findings with increased concentrations of PTH (164.8 Ϯ 14.4 pg/ml), increased total calcium levels (2.88 Ϯ 0.04 mmol/l), and decreased levels of inorganic phosphate (2.42 Ϯ 0.11 mg/dl). All other measured parameters were within normal limits (see Table 1 ).
The patients suffered from the following typical concomitant PHPT-dependent disorders: eight from nephrolithiasis (36%), eight from osteopenia (36%), one from gastritis (4.5%), one from gallstones (4.5%), and one from acral paresthesia (4.5%). In addition, 13 patients had multinodular goiter (59%), two had papillary thyroid carcinoma (9%), eight had arterial hypertension (36%), two had coronary artery disease (9%), and one had diabetes mellitus (4.5%) (see Table 2 ).
BMC in peripheral blood. In patients suffering from PHPT, (Fig. 1) . In eight patients who agreed to followup examinations (16.7 Ϯ 2.3 mo after surgery), the numbers of all characterized subpopulations were reduced significantly compared with the preoperative BMC levels (Fig. 2) . The menopausal status did not affect the number of circulating BMC. Seven postmenopausal patients showed comparable numbers of BMC with the other patients (data not shown).
Cytokine serum levels. Serum levels of SDF-1 were significantly elevated in patients with PHPT compared with controls (1,781.5 Ϯ 105.9 vs. 1,431.3 Ϯ 40.8 pg/ml, P Ͻ 0.05). In addition, VEGF serum concentrations were significantly elevated (80.2 Ϯ 9.5 vs. 46.5 Ϯ 8.0 pg/ml, P Ͻ 0.05). In contrast, serum levels of G-CSF were significantly decreased (16.8 Ϯ 1.5 vs. 30.9 Ϯ 5.0 pg/ml, P Ͻ 0.05). Serum levels of SCF and EPO remained unchanged [SCF: 746.0 Ϯ 62.8 vs. 741.8 Ϯ Values are means Ϯ SE for n ϭ 22 primary hyperparathyroidism (PHPT) patients and 10 controls. Relevant laboratory parameters in our study population. PTH, parathyroid hormone; Ca, calcium; PO4, phosphate; Cr, creatinine; BUN, blood urea nitrogen; FT3, free triiodothyronine; FT4, free thyroxine. 
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ϩ cells (r ϭ 0.71, P Ͻ 0.05; see Fig. 4 ). No correlation was detected between cytokine serum levels and circulating BMC or PTH (Table 3) .
DISCUSSION
In our prospective study we showed a significant effect on mobilization of BMC in patients suffering from parathyroid adenoma. Serum levels of PTH were positively correlated with the number of circulating progenitor cells, which decreased to normal levels after removal of the adenoma. In addition, we demonstrated increased serum levels of SDF-1 and VEGF in PHPT patients. However, there was no correlation between cytokine serum levels (SDF-1, VEGF) and circulating BMCs. Serum levels of G-CSF, EPO, and SCF known to mobilize BMC were even decreased or remained unchanged, suggesting a direct effect of PTH on stem cell mobilization.
PTH is a key hormone regulating calcium and phosphate homeostasis. Recently, Calvi et al. (4) demonstrated direct effects of PTH on the hematopoietic system in a mouse model. Overexpression of the human PTH/PTH-related peptide receptor under control of the osteoblast-specific ␣1(I) collagen promoter resulted in an increase of Sca-1 and c-kit-positive stem cells in the bone marrow. PTH treatment of lethally irradiated wild-type mice resulted in an improved survival after bone marrow transplantation. The impact of PTH on mobilization of BMC into peripheral blood was not investigated. Here, we used a natural model of permanent PTH stimulation in humans suffering from parathyroid adenomas. Our prospective trial showed an increase of circulating BMC in these patients for the first time.
To investigate the mechanism for mobilization we analyzed several cytokines, such as G-CSF, VEGF, SDF-1, SCF, and EPO, that are known to stimulate bone marrow for release of stem cells into the circulation (2, 11, 24) . Activated osteoblasts, which are among other structural cells in the hematopoietic stem cell niche, are able to produce growth factors such as G-CSF and SDF-1 (18, 22, 29 -31) . In our study, G-CSF was even downregulated, and serum levels of SCF and EPO remained unchanged. Interestingly, our data showed a significant increase of SDF-1 and VEGF in peripheral blood. This is consistent with a study from Lazaris et al. (20) showing an upregulation of VEGF and VEGF receptor in immunostaining of parathyroid adenomas. However, SDF-1 and VEGF did not correlate with the number of circulating BMC. In contrast, PTH showed a significant positive correlation with mobilized BMC. This strongly indicates that PTH is the effector for BMC mobilization.
BMC are known to contribute to neovascularization and vessel repair, as revealed in studies showing increased mobilization of EPC in conditions of ischemia and vessel injury (8, 9, 13, 19, 28, 32, 34, 36) . Our results showed that numbers of circulating BMC significantly decreased to normal levels after removal of the adenoma, suggesting that mobilization of BMC occurs as a consequence of high PTH concentrations and thus may play a role in the pathophysiology of the formation of parathyroid adenomas. It has been demonstrated (25, 26) that EPC may infiltrate tumors and give rise to up to 16% of the tumor neovascularization. The mobilization of EPC in PHPT may also contribute to angiogenesis in parathyroid adenomas, and thus PTH-dependent mobilization of BMC may promote adenoma growth.
Our study showed for the first time that elevated PTH serum levels result in increased mobilization of BMCs into peripheral Fig. 3 . Cytokine serum levels measured by ELISA. PHPT results in significantly elevated serum levels of VEGF and stromal cell-derived factor 1 (SDF-1), whereas granulocyte colony-stimulating factor (G-CSF) levels are significantly downregulated. Stem cell factor (SCF) and erythropoietin (EPO) serum levels remained unchanged. A: serum levels of VEGF. B: serum levels of SDF-1. C: serum levels of G-CSF. D: serum levels of SCF. E: serum levels of EPO. *P Ͻ 0.05. Error bars designated as SE.
blood. This may enhance angiogenesis in parathyroid adenoma and support tumor growth. However, further studies are necessary to evaluate the exact role of mobilized BMC in PHPT.
In summary, our results offer new insights into the function of PTH and pathophysiology of PHPT and thus may provide new options for diagnosis and treatment of the disease. Furthermore, our data may pave the way for PTH as a novel substance for mobilization of BMCs. BMC, bone marrow-derived progenitor cells; SDF-1, stromal cell-derived factor 1; SCF, stem cell factor; EPO, erythropoietin; G-CSF, granulocyte colony-stimulating factor. Correlations of PTH and cytokine serum levels with circulating BMC. Nos. indicate correlation coefficient. *P Ͻ 0.05.
